Research & Development
-
Stock via Getty Images
As gene therapies falter on the market, this biopharma is aiming to defy the odds
After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.
By Meagan Parrish • Aug. 8, 2025 -
Permission granted by AstraZeneca
Q&AInside AstraZeneca’s long-game strategy in lung cancer
New long-term results for Tagrisso in EGFR-mutated non-small cell lung cancer showcase a precision approach the company has honed for decades.
By Michael Gibney • Aug. 7, 2025 -
Explore the Trendline➔
Stock via Getty Images
TrendlineRare diseases
As drug developers find promise in the rare diseases, deals and treatments are on the rise
By PharmaVoice staff -
Permission granted by Vertex Pharmaceuticals
David Altshuler, geneticist who helped transform Vertex, to retire next year
Since becoming Vertex's top scientist in 2015, Altshuler has helped the company become an industry powerhouse. He’ll depart next year in a “planned transition.”
By Ben Fidler • Aug. 5, 2025 -
Courtesy of Merck & Co.
Merck & Co. assembles an Alzheimer’s comeback with a next-gen precision focus
With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater understanding of its drivers.
By Michael Gibney • Aug. 1, 2025 -
Permission granted by Roche
Roche pushes ahead with late-comer strategy in obesity
The Swiss pharma company announced several updates to its obesity portfolio in its latest earnings report.
By Amy Baxter • July 30, 2025 -
Stock via Getty Images
Biotech investing is down, but some VC firms are bucking the trend
Discipline is the name of the game after a glut of over-investing burst the biotech bubble.
By Alexandra Pecci • July 29, 2025 -
Permission granted by Merck & Co.
Could bispecifics unseat Keytruda from its oncology throne?
Signals suggest the drugs could improve on the standard of care, but the market may not make it easy for another megablockbuster to rise to the top.
By Kelly Bilodeau • July 28, 2025 -
E+ via Getty Images
From the bench: Researchers make NIH-funded preclinical strides in mRNA and obesity
The studies are contributing preclinical advances for some of the world’s biggest blockbusters.
By Michael Gibney • July 25, 2025 -
Courtesy of BMS
How Bristol Myers Squibb uses AI to validate drugs before they’re even in the lab
The company’s AI approach allows molecule candidates to be vetted for efficacy and other properties early in development.
By Alexandra Pecci • July 24, 2025 -
Mario Guti via Getty Images
Who is Dr. George Tidmarsh, the new director of CDER?
Despite past criticism of public health policies, Tidmarsh recently praised the FDA and said he’ll focus on boosting review efficiencies.
By Meagan Parrish and Michael Gibney • July 23, 2025 -
Adobe Stock / EVERST
Sponsored by TriNetXClosing the gap: How real-world data and artificial intelligence are reinventing the last mile of clinical research
Clinical trial delays are costly—here’s how RWD and AI are transforming recruitment and retention.
July 21, 2025 -
Stock via Getty Images
FDA invites more data from abroad — with a wary eye on China
The FDA approved four drugs last year without any U.S. trial participants, but has maintained a tougher stance on China, even as it grows into an R&D powerhouse.
By Amy Baxter • July 16, 2025 -
Jason Doiy via Getty Images
With Verona deal, Merck wagers on strength of lung drug’s patents
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make good on the deal, other secondary patents will need to hold up.
By Jonathan Gardner • July 11, 2025 -
Jan Sonnenmair via Getty Images
Early measles drug R&D kicks into gear as U.S. records record outbreak
Several companies have announced preclinical efforts to develop the first-ever measles treatment.
By Meagan Parrish • July 11, 2025 -
Stock via Getty Images
First 90 DaysAs its cancer vaccine moves through the clinic, Transgene sets sights on manufacturing
Simone Steiner recently joined the French company to set the stage for launch.
By Amy Baxter • July 9, 2025 -
Stock via Getty Images
The MEK effect on cancer — a slow and steady approach to drug resistance
Immuneering Corporation’s investigational MEK inhibitor aims to outpace cancer while reducing resistance and side effects.
By Kelly Bilodeau • July 8, 2025 -
stock via Getty Images
GLP-1 roadblocks: Discontinuation rates soar as insurers clamp down
As more drugmakers aim for the lucrative weight loss market, patient challenges linger.
By Amy Baxter • July 7, 2025 -
E+ via Getty Images
Can China sustain a surge in oncology drug innovation?
The country’s trajectory may get a boost from anticipated results of a Keytruda rival’s U.S. trials.
By Kelly Bilodeau • July 2, 2025 -
Stock via Getty Images
First 90 DaysA biopharma bolsters patient centricity and trial diversity goals through newly created role
Ardelyx’s newly minted chief patient officer is infusing patient experiences into every element of the business.
By Alexandra Pecci • July 1, 2025 -
iStock via Getty Images
AI’s ‘massive transition’ in biopharma shapes leadership mindsets — tension and all
The AI revolution is driving tension between new technology and the traditional approaches in drugmaking. Biopharma leaders are trying to navigate those turbulent waters.
By Michael Gibney • July 1, 2025 -
Grandbrothers via Getty Images
Biopharma is on edge about NIH funding cuts and what the future holds for research
Proposed cuts to public funding for early science have led to an outcry in scientific circles. For biopharma leaders, the effects are still up in the air.
By Michael Gibney • June 26, 2025 -
Stock via Getty Images
After myriad failures, a new wave of ALS drugs approaches
Several drugmakers anticipate trial results and FDA submissions in 2025 and 2026, including some still overcoming past failures.
By Amy Baxter • June 25, 2025 -
Permission granted by Parabilis
Q&AHow a Big Pharma veteran looks to stand out in biotech as a unique ‘drug hunter’
J&J’s former head of R&D, now CEO of Parabilis Medicines, aims to remain above the biotech fray by taking on unique targets from which others have steered clear.
By Michael Gibney • June 24, 2025 -
iStock via Getty Images
Biotech’s turning point: for every challenge, an opportunity in disguise
As hurdles litter biotech’s future, forward-thinking leaders look for ways to leap to the other side.
By Michael Gibney • June 20, 2025 -
Permission granted by Novartis
ProfileThe former Wall Street analyst shaping Novartis’ big-picture strategy
Ronny Gal, chief strategy and growth officer at Novartis, is guiding the company into a new era shaped by science-minded M&A and a slimmed-down pivot.
By Michael Gibney • June 10, 2025
